1. Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany;
2. European Myelodysplastic Syndromes Cooperative Group (EMSCO Group), Leipzig, Germany;
3. Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, and Université Paris 7, Paris, France;
4. Klinik für Onkologie, Hämatologie und Palliativmedizin, Marien Hospital, Düsseldorf, Germany;
5. Azienda Ospedaliero Universitaria (AOU) Careggi, University of Florence, Florence, Italy;
6. Department of Haematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands;
7. St. James’s Institute of Oncology, Leeds Teaching Hospitals, Leeds, United Kingdom;
8. Department of Tumor Immunology, Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands;
9. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;
10. Division of Haematology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden;
11. Department of Haematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany;
12. Department of Internal Medicine V (Hematology and Oncology), Medical University Innsbruck, Innsbruck, Austria;
13. Department of Haematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, University of Pavia, Pavia, Italy;
14. Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; and
15. Dana-Farber Cancer Institute, Boston, MA